Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer
Clinical Drug Investigation · 2024-08 · 44 (8) · 553-576
DOI: 10.1007/s40261-024-01379-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Drug Investigation, online erschienen am 31.07.2024. Verfasst von Edurne Arriola und 15 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Hospital del Mar, Center for Biomedical Network Research on Cancer (CIBERONC), Barcelona, Spain. earriola@psmar.cat. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lactams, Lung Neoplasms, Anaplastic Lymphoma Kinase. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Themen: Patientensicherheit
Abstract (Originalsprache)
The use of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), such as lorlatinib, for the treatment of patients with ALK gene rearrangement (or ALK-positive) non-small cell lung cancer (NSCLC) has been shown to improve the overall survival and quality of life of these patients. However, lorlatinib is not exempt from potential adverse events. Adequate monitoring and management of these adverse events are critical for increasing patient adherence to lorlatinib, thereby maximizing the benefits of treatment and minimizing the risks associated with treatment discontinuation. Considering that the adverse events of lorlatinib can affect different organs and systems, the participation of a multidisciplinary team, including cardiologists, neurologists, internal medicine specialists, and oncology pharmacists, is needed. This article presents specific and pragmatic strategies for identifying and treating the most relevant adverse events associated with lorlatinib in patients with advanced ALK-positive NSCLC based on the clinical experience of a multidisciplinary panel of experts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Oncology Department, Hospital del Mar, Center for Biomedical Network Research on Cancer (CIBERONC), Barcelona, Spain. earriola@psmar.cat.
- Medical Oncology Department, La Paz University Hospital, Hospital La Paz Health Research Institute (IdiPAZ), Center for Biomedical Network Research on Cancer (CIBERONC), Madrid, Spain.
- Medical Oncology Department, A Coruña University Hospital, Biomedical Research Institute of A Coruña (INIBIC), A Coruña, Spain.
- Oncological Pharmacy Unit, Santiago de Compostela University Clinical Hospital, Health Research Institute of Santiago de Compostela (IDIS), University of Santiago de Compostela, A Coruña, Spain.
- Medical Oncology Department, Virgen del Rocío University Hospital, Biomedicine Institute of Sevilla (IBIS), University of Sevilla, Sevilla, Spain.
- Neuro-Oncology Unit, Bellvitge University Hospital, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Förderung
- Pfizer
Zitieren
APA
Arriola, E., de Castro, J., García-Campelo, R., Bernárdez, B., Bernabé, R., Bruna, J., Dómine, M., Isla, D., Juan-Vidal, Ó., López-Fernández, T., Nadal, E., Rodríguez-Abreu, D., Vares, M., Asensio, Ú., García, L. F., & Felip, E. (2024). Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer. Clinical Drug Investigation, 44(8), 553-576. https://doi.org/10.1007/s40261-024-01379-7
Vancouver
Arriola E, de Castro J, García-Campelo R, Bernárdez B, Bernabé R, Bruna J, et al. Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer. Clinical Drug Investigation. 2024;44(8):553-576. doi:10.1007/s40261-024-01379-7
BibTeX
@article{Arriola2024,
author = {Arriola, Edurne and de Castro, Javier and García-Campelo, Rosario and Bernárdez, Beatriz and Bernabé, Reyes and Bruna, Jordi and Dómine, Manuel and Isla, Dolores and Juan-Vidal, Óscar and López-Fernández, Teresa and Nadal, Ernest and Rodríguez-Abreu, Delvys and Vares, María and Asensio, Úrsula and García, Luis F and Felip, Enriqueta},
title = {Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer},
journal = {Clinical Drug Investigation},
year = {2024},
volume = {44},
number = {8},
pages = {553--576},
doi = {10.1007/s40261-024-01379-7}
}
EUVIMED